Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 4, 2014, Pages 2191-2199

  Lee, Junyeop ^a,b,c   Park, Dae Young ^a,b   Park, Do Young ^a,b   Park, Intae ^a,b   Chang, Woohyok ^d   Nakaoka, Yoshikazu ^e   Komuro, Issei ^f   Yoo, Ook Joon ^a,b   Koh, Gou Young ^a,b  

^a National Research Laboratory of Vascular Biology and Stem Cells Graduate School of Medical Science and Engineering   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Yeungnam University College of Medicine   (South Korea)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

Age related macular degeneration; Angiopoietin 1; Choroidal neovascularization; Vascular leakage

Indexed keywords

AFLIBERCEPT; ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; CD31 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYCLONAL ANTIBODY; PROTEIN ZO1; STROMAL CELL DERIVED FACTOR 1; TAMOXIFEN; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CAPILLARY LEAK SYNDROME; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; GENE DELETION; IMMUNOHISTOCHEMISTRY; INDOCYANINE GREEN ANGIOGRAPHY; INTRACELLULAR SIGNALING; LASER COAGULATION; MACROPHAGE MIGRATION INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBRETINAL NEOVASCULARIZATION; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; VASCULAR LEAKAGE; WESTERN BLOTTING;

AGE-RELATED MACULAR DEGENERATION; ANGIOPOIETIN-1; CHOROIDAL NEOVASCULARIZATION; VASCULAR LEAKAGE;

ANGIOPOIETIN-1; ANIMALS; BLOTTING, WESTERN; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INTRAVITREAL INJECTIONS; MICE; MICE, TRANSGENIC; RNA;

EID: 84898723171     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-13897     Document Type: Article

References (42)

1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379:1728-1738.
2. Holz FG, Pauleikhoff D, Klein R, Bird AC. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol. 2004;137:504-510.
3. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606-2617.
4. Heier JS, Brown DM, Chong V, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology. 2012;119:2537-2548.
5. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119: 1388-1398.
6. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56:95-113.
7. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol. 2007;91:1318-1322.
8. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008;115:2199-2205.
9. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative agerelated macular degeneration. Retina. 2009;29:723-731.
10. Tatar O, Yoeruek E, Szurman P, et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol. 2008;126:782-790.
11. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009;10:165-177.
12. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
13. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 2000;6: 460-463.
14. Cho CH, Kim KE, Byun J, et al. Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ Res. 2005;97:86-94.
15. Uemura A, Ogawa M, Hirashima M, et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest. 2002;110:1619-1628.
16. Lee J, Kim KE, Choi DK, et al. Angiopoietin-1 guides directional angiogenesis through integrin alphavbeta5 signaling for recovery of ischemic retinopathy. Sci Transl Med. 2013;5:203ra127.
17. Koh GY. Orchestral actions of angiopoietin-1 in vascular regeneration. Trends Mol Med. 2013;19:31-39.
18. Gamble JR, Drew J, Trezise L, et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res. 2000;87:603-607.
19. Kim I, Moon SO, Park SK, Chae SW, Koh GY. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res. 2001;89:477-479.
20. Nambu H, Nambu R, Oshima Y, et al. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther. 2004;11:865-873.
21. Nambu H, Umeda N, Kachi S, et al. Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization. J Cell Physiol. 2005;204:227-235.
22. Wang Y, Bi H, Teng D, et al. Potential protective effect of angiopoietin-1 on the leakage of rat choroidal neovascularization. Saudi Med J. 2013;34:584-590.
23. Cho CH, Kammerer RA, Lee HJ, et al. Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101: 5553-5558.
24. Hato T, Kimura Y, Morisada T, et al. Angiopoietins contribute to lung development by regulating pulmonary vascular network formation. Biochem Biophys Res Commun. 2009; 381:218-223.
25. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999;21:70-71.
26. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998;153:1641-1646.
27. Koh YJ, Kim HZ, Hwang SI, et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell. 2010;18:171-184.
28. Campos M, Amaral J, Becerra SP, Fariss RN. A novel imaging technique for experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2006;47:5163-5170.
29. Saishin Y, Takahashi K, Lima e, Silva R, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003; 195:241-248.
30. Yu H, Wang P, An P, Xue Y. Recombinant human angiopoietin-1 ameliorates the expressions of ZO-1, occludin, VE-cadherin, and PKCalpha signaling after focal cerebral ischemia/reperfusion in rats. J Mol Neurosci. 2012;46:236-247.
31. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8:1223-1234.
32. Wang W, Dentler WL, Borchardt RT. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol. 2001;280:H434-H440.
33. Murakami T, Felinski EA, Antonetti DA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem. 2009;284:21036-21046.
34. Giannotta M, Trani M, Dejana E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell. 2013;26:441-454.
35. Kim KE, Cho CH, Kim HZ, Baluk P, McDonald DM, Koh GY. In vivo actions of angiopoietins on quiescent and remodeling blood and lymphatic vessels in mouse airways and skin. Arterioscler Thromb Vasc Biol. 2007;27:564-570.
36. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3578-3585.
37. Espinosa-Heidmann DG, Caicedo A, Hernandez EP, Csaky KG, Cousins SW. Bone marrow-derived progenitor cells contribute to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:4914-4919.
38. Gu H, Cui M, Bai Y, et al. Angiopoietin-1/Tie2 signaling pathway inhibits lipopolysaccharide-induced activation of RAW264.7 macrophage cells. Biochem Biophys Res Commun. 2010;392:178-182.
39. Gavard J, Patel V, Gutkind JS. Angiopoietin-1 prevents VEGFinduced endothelial permeability by sequestering Src through mDia. Dev Cell. 2008;14:25-36.
40. Ngok SP, Geyer R, Liu M, et al. VEGF and Angiopoietin-1 exert opposing effects on cell junctions by regulating the Rho GEF Syx. J Cell Biol. 2012;199:1103-1115.
41. Otani A, Takagi H, Oh H, Koyama S, Matsumura M, Honda Y. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40: 1912-1920.
42. Hangai M, Murata T, Miyawaki N, et al. Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:1617-1625.